COLLPLANT BIOTECHNOLOGIES REPORTS 2024 SECOND QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
CollPlant Biotechnologies (NASDAQ: CLGN) reported Q2 2024 financial results and provided a corporate update. Key highlights include:
- Initiated pre-clinical trial with 200cc rhCollagen-based regenerative breast implants printed with Stratasys' Origin® 3D printer
- Breast implants could address a $3.0 billion market opportunity
- Q2 revenues were $249,000, down from $10.2 million in Q2 2023 due to a one-time milestone payment in the prior year
- Q2 GAAP net loss was $4.2 million or $0.37 per share
- Cash and cash equivalents of $18.9 million as of June 30, 2024
- Cash runway expected to last until at least the end of 2025
The company is advancing its regenerative breast implant program and released its first ESG report. CollPlant aims to lead in regenerative medicine with its innovative collagen technology.
CollPlant Biotechnologies (NASDAQ: CLGN) ha riportato i risultati finanziari del secondo trimestre del 2024 e fornito un aggiornamento aziendale. I punti salienti includono:
- Avviato uno studio preclinico con impianti mammari rigenerativi basati su rhCollagen stampati con la stampante 3D Origin® di Stratasys
- Gli impianti mammari potrebbero affrontare un mercato da 3,0 miliardi di dollari
- I ricavi del secondo trimestre sono stati di 249.000 dollari, in calo rispetto ai 10,2 milioni di dollari del secondo trimestre 2023 a causa di un pagamento una tantum per un traguardo nell’anno precedente
- La perdita netta GAAP del secondo trimestre è stata di 4,2 milioni di dollari, pari a 0,37 dollari per azione
- Disponibilità liquide e equivalenti di 18,9 milioni di dollari al 30 giugno 2024
- La liquidità è prevista durare fino alla fine del 2025
L'azienda sta avanzando il suo programma di impianti mammari rigenerativi e ha rilasciato il suo primo rapporto ESG. CollPlant mira a diventare leader nella medicina rigenerativa con la sua innovativa tecnologia del collagene.
CollPlant Biotechnologies (NASDAQ: CLGN) reportó los resultados financieros del segundo trimestre de 2024 y proporcionó una actualización corporativa. Los aspectos más destacados incluyen:
- Iniciado un ensayo preclínico con implantes mamarios regenerativos basados en rhCollagen impresos con la impresora 3D Origin® de Stratasys
- Los implantes mamarios podrían abordar una oportunidad de mercado de 3,0 mil millones de dólares
- Los ingresos del segundo trimestre fueron de 249.000 dólares, una disminución desde los 10,2 millones de dólares en el segundo trimestre de 2023 debido a un pago único por un hito en el año anterior
- La pérdida neta GAAP del segundo trimestre fue de 4,2 millones de dólares o 0,37 dólares por acción
- El efectivo y equivalentes de efectivo eran 18,9 millones de dólares al 30 de junio de 2024
- Se espera que la liquidación de efectivo dure hasta al menos finales de 2025
La empresa está avanzando en su programa de implantes mamarios regenerativos y lanzó su primer informe ESG. CollPlant busca liderar en medicina regenerativa con su innovadora tecnología de colágeno.
CollPlant Biotechnologies (NASDAQ: CLGN)은 2024년 2분기 재무 결과를 보고하고 기업 업데이트를 제공했습니다. 주요 내용은 다음과 같습니다:
- Stratasys의 Origin® 3D 프린터로 인쇄된 rhCollagen 기반의 재생 유방 임플란트에 대한 전임상 시험 시작
- 유방 임플란트는 30억 달러의 시장 기회를 해결할 수 있습니다
- 2분기 수익은 249,000달러로, 지난해 2분기 1,020만 달러에서 감소했으며 이는 전년도의 일회성 이정표 지불 때문입니다
- 2분기 GAAP 순손실은 420만 달러 또는 주당 0.37달러였습니다
- 2024년 6월 30일 기준 현금 및 현금성 자산은 1,890만 달러였습니다
- 현금 소진 기간은 2025년 말까지 지속될 것으로 예상됩니다
회사는 재생 유방 임플란트 프로그램을 발전시키고 있으며 첫 번째 ESG 보고서를 발표했습니다. CollPlant는 혁신적인 콜라겐 기술로 재생 의학의 선두주자가 되는 것을 목표로 하고 있습니다.
CollPlant Biotechnologies (NASDAQ: CLGN) a rapporté les résultats financiers du deuxième trimestre 2024 et a fourni une mise à jour sur l'entreprise. Les faits saillants comprennent :
- Lancement d'un essai préclinique avec des implants mammaires régénératifs à base de rhCollagen imprimés avec l'imprimante 3D Origin® de Stratasys
- Les implants mammaires pourraient représenter une opportunité de marché de 3,0 milliards de dollars
- Les revenus du deuxième trimestre se sont élevés à 249 000 dollars, en baisse par rapport à 10,2 millions de dollars au deuxième trimestre 2023 en raison d'un paiement unique pour un jalon l'année précédente
- La perte nette GAAP du deuxième trimestre était de 4,2 millions de dollars, soit 0,37 dollar par action
- Trésorerie et équivalents de trésorerie de 18,9 millions de dollars au 30 juin 2024
- La durée de liquidité devrait durer jusqu'à au moins fin 2025
L'entreprise fait progresser son programme d'implants mammaires régénératifs et a publié son premier rapport ESG. CollPlant vise à devenir un leader dans la médecine régénérative grâce à sa technologie innovante du collagène.
CollPlant Biotechnologies (NASDAQ: CLGN) hat die finanziellen Ergebnisse für das zweite Quartal 2024 veröffentlicht und ein Unternehmens-Update bereitgestellt. Die wichtigsten Punkte umfassen:
- Beginn einer präklinischen Studie mit rhCollagen-basierten regenerativen Brustimplantaten, die mit dem 3D-Drucker Origin® von Stratasys gedruckt wurden
- Brustimplantate könnten ein Marktpotenzial von 3,0 Milliarden US-Dollar bedienen
- Die Einnahmen im 2. Quartal lagen bei 249.000 US-Dollar, im Vergleich zu 10,2 Millionen US-Dollar im 2. Quartal 2023, bedingt durch eine Einmalzahlung im Vorjahr
- Der GAAP-Nettoverlust im 2. Quartal betrug 4,2 Millionen US-Dollar oder 0,37 US-Dollar pro Aktie
- Flüssige Mittel und flüssige Mitteläquivalente von 18,9 Millionen US-Dollar zum 30. Juni 2024
- Die finanzielle Liquidität wird voraussichtlich bis mindestens Ende 2025 ausreichen
Das Unternehmen fördert sein Programm für regenerative Brustimplantate und hat seinen ersten ESG-Bericht veröffentlicht. CollPlant strebt an, mit seiner innovativen Kollagen-Technologie führend in der regenerativen Medizin zu sein.
- Initiated pre-clinical trial for 200cc rhCollagen-based regenerative breast implants
- Breast implants could address a $3.0 billion market opportunity
- Cash runway expected to last until at least the end of 2025
- Released first ESG and Sustainability report
- Q2 revenues decreased to $249,000 from $10.2 million in Q2 2023
- Q2 GAAP net loss of $4.2 million compared to net income of $5.8 million in Q2 2023
- Six-month GAAP net loss of $8.4 million compared to net income of $2.0 million in the same period of 2023
Insights
CollPlant's Q2 2024 results show a significant revenue decline to
The company reported a net loss of
On a positive note, CollPlant maintains a strong cash position of
CollPlant's initiation of a pre-clinical trial for its 200cc rhCollagen-based regenerative breast implants marks a significant milestone in the field of regenerative medicine. The company's collaboration with Stratasys for 3D printing these implants demonstrates innovative approach to manufacturing.
Previous pre-clinical results showing tissue regeneration and vascularization are promising, potentially offering a revolutionary alternative to current breast implants. This could address long-standing issues with traditional implants, such as capsular contracture and implant replacement needs.
However, it's important to note that the path to market is long for such innovative medical devices. Investors should be prepared for an extended development timeline, including rigorous clinical trials and regulatory approvals before any potential commercialization.
CollPlant's release of its inaugural ESG and Sustainability Report demonstrates a commitment to transparency and responsible business practices. This is increasingly important for investors who consider ESG factors in their decision-making process.
The company's focus on plant-based production of collagen aligns well with sustainability trends, potentially reducing environmental impact compared to animal-derived alternatives. Their efforts to reduce emissions and deliver safe, reliable medical solutions also contribute positively to their ESG profile.
However, as this is their first report, investors should look for concrete metrics and progress in future updates to assess the real impact of these initiatives. The alignment of CollPlant's operations with ethical commitments could enhance its appeal to ESG-focused investors and potentially open up new funding opportunities.
- Recently initiated a pre-clinical trial with CollPlant's rhCollagen-based regenerative breast implants, printed with Stratasys' Origin® 3D printer that are 200cc in volume
- Breast implants could address a
- Cash and cash equivalents balance as of June 30, 2024 was
- Conference call to be held today at 10:00 a.m.
REHOVOT,
"We made notable development progress this quarter advancing our regenerative breast implant program," commented Yehiel Tal, Chief Executive Officer of CollPlant Biotechnologies. "This month we launched a pre-clinical trial with 200cc commercial-sized breast implants printed with Stratasys' Origin® 3D printer. This is an important milestone for us since currently there are no other commercial products that allow regeneration of soft tissues such as the breast. The previous pre-clinical results we've seen have been encouraging, such as tissue regeneration and vascularization, and we are looking forward to reporting more results in the fourth quarter of 2024 and in the first quarter of 2025."
Mr. Tal continued, "We also released our first ESG and Sustainability report after establishing a corporate sustainability strategy with clear targets in key areas that we believe are crucial to our stakeholders. I would like to emphasize that our overall strategy is driven by our vision to lead in regenerative medicine and improve global health with our innovative collagen technology. This first report includes tangible steps we are taking towards enabling a sustainable future."
Q2 and Recent Program Highlights
- Earlier in August, 2024, CollPlant and Stratasys Ltd. (Nasdaq: SSYS), a leader in polymer 3D printing solutions, announced the initiation of a pre-clinical study with CollPlant's 200cc commercial-sized implants printed on Stratasys' Origin 3D printer. The collaboration between CollPlant and Stratasys is currently focused on the development of a bioprinting solution for CollPlant's breast implants, in addition to finding solutions to scale-up the implant's fabrication process. If successfully developed, the novel implants could provide a revolutionary alternative to the implants that are currently on the market.
- In June, 2024, CollPlant announced that it successfully printed for the first time, 200 cc-sized regenerative breast implants, the same size that are now in pre-clinical testing with Stratasys. CollPlant also announced additional, positive, interim preclinical data from ongoing large-animal studies, evaluating its regenerative breast implants.
ESG Updates
In July, 2024, CollPlant announced the release of its inaugural Environmental, Social and Corporate Governance (ESG) and Sustainability Report covering the fiscal year 2023.
CollPlant's first report details the initiatives that it has taken to adopt an ESG strategy with a focus on the pillars that represent the areas with the highest impact. By aligning the Company's operations with its ethical commitments, the Company plans to enhance plant-based production, reduce emissions, and deliver safe and reliable medical solutions. The report reflects CollPlant's wide commitment to fostering environmental sustainability and enhancing human health, as well as advancing social and corporate governance objectives that contribute to the Company's impact.
Three and Six Month-Period Ended June 30, 2024 Financial Results
GAAP revenues for the second quarter ended June 30, 2024, were
GAAP revenues for the six months ended June 30, 2024, were
GAAP cost of revenues for the second quarter ended June 30, 2024, was
GAAP cost of revenues for the six months ended June 30, 2024, was
GAAP gross loss for the second quarter ended June 30, 2024, was
GAAP gross loss for the six months ended June 30, 2024, was
GAAP operating expenses for the second quarter ended June 30, 2024, were
GAAP operating expenses for the six months ended June 30, 2024, were
GAAP financial income, net, for the second quarter ended June 30, 2024, totaled
GAAP financial income, net, for the six months ended June 30, 2024, totaled
GAAP net loss for the second quarter ended June 30, 2024, was
GAAP net loss for the six months ended June 30, 2024, was
Balance Sheet and Cash Flow
Cash and cash equivalents as of June 30, 2024, were
Cash used in operating activities during the six months ended June 30, 2024, and during the six months ended June 30, 2023, was
Cash used in investing activities during the six months ended June 30, 2024, was
Cash provided by financing activities during the six months ended June 30, 2024 was
Conference call information
To participate in the conference call, please use the dial-in information below:
Investors outside of the U.S.: 1-201-493-6779
Conference ID: 13746304
Note, you can avoid long wait times for the operator by using the Call me™ feature and clicking the link below 15 minutes prior to the scheduled call start time:
https://callme.viavid.com/viavid/?callme=true&passcode=13728588&h=true&info=company-email&r=true&B=6
Webcast information
A live webcast will also be available in listen-only mode and can be accessed here or via the link to be posted on the News & Events section of the CollPlant Investor relations website. A replay of the webcast will be available following the conclusion of the live broadcast and will be accessible on the Company's website for a limited time.
Submit questions to management in advance of the call
To ask management a question ahead of the call, please email Dan Ferry at LifeSci Advisors LLC up until 24 hours before the event at daniel@lifesciadvisors.com.
COLLPLANT BIOTECHNOLOGIES LTD. | ||||||||
June 30, | December 31, | |||||||
2024 | 2023 | |||||||
(Unaudited) | ||||||||
Assets | ||||||||
Current assets: | ||||||||
Cash and cash equivalents | $ | 18,920 | $ | 26,674 | ||||
Restricted deposit | 236 | 241 | ||||||
Trade receivables, net | 250 | - | ||||||
Inventories | 439 | 714 | ||||||
Other accounts receivable and prepaid expenses | 490 | 393 | ||||||
Total current assets | 20,335 | 28,022 | ||||||
Non-current assets: | ||||||||
Restricted deposit | 113 | 57 | ||||||
Operating lease right-of-use assets | 3,398 | 3,070 | ||||||
Property and equipment, net | 2,561 | 2,789 | ||||||
Intangible assets, net | 159 | 188 | ||||||
Total non-current assets | 6,231 | 6,104 | ||||||
Total assets | $ | 26,566 | $ | 34,126 | ||||
COLLPLANT BIOTECHNOLOGIES LTD. | ||||||||
June 30, | December 31, | |||||||
2024 | 2023 | |||||||
(Unaudited) | ||||||||
Liabilities and shareholders' equity | ||||||||
Current liabilities: | ||||||||
Trade payables | $ | 1,138 | $ | 980 | ||||
Operating lease liabilities | 789 | 624 | ||||||
Accrued liabilities and other | 1,314 | 1,647 | ||||||
Total current liabilities | 3,241 | 3,251 | ||||||
Non-current liabilities: | ||||||||
Operating lease liabilities | 2,596 | 2,535 | ||||||
Total non-current liabilities | 2,596 | 2,535 | ||||||
Total liabilities | 5,837 | 5,786 | ||||||
Commitments and contingencies | ||||||||
Shareholders' Equity: | ||||||||
Ordinary shares, NIS 1.5 par value - authorized: 30,000,000 ordinary shares as of | 4,983 | 4,982 | ||||||
Additional paid in capital | 121,861 | 121,068 | ||||||
Accumulated other comprehensive loss | (969) | (969) | ||||||
Accumulated deficit | (105,146) | (96,741) | ||||||
Total shareholders' equity | 20,729 | 28,340 | ||||||
Total liabilities and shareholders' equity | $ | 26,566 | $ | 34,126 | ||||
COLLPLANT BIOTECHNOLOGIES LTD. | ||||||||||||||||
Six months ended | Three months ended | |||||||||||||||
2024 | 2023 | 2024 | 2023 | |||||||||||||
Revenues | $ | 347 | $ | 10,617 | $ | 249 | $ | 10,184 | ||||||||
Cost of revenues | 1,081 | 940 | 536 | 615 | ||||||||||||
Gross profit (loss) | (734) | 9,677 | (287) | 9,569 | ||||||||||||
Operating expenses: | ||||||||||||||||
Research and development | 5,103 | 4,676 | 2,697 | 2,574 | ||||||||||||
General, administrative and marketing | 2,898 | 2,843 | 1,422 | 1,318 | ||||||||||||
Total operating income (loss) | (8,735) | 2,158 | (4,406) | 5,677 | ||||||||||||
Financial income (expenses), net | 330 | (111) | 196 | 85 | ||||||||||||
Net income (loss) for the period | $ | (8,405) | $ | 2,047 | $ | (4,210) | $ | 5,762 | ||||||||
Basic net income (loss) per ordinary share | $ | (0.73) | $ | 0.18 | $ | (0.37) | $ | 0.51 | ||||||||
Diluted net income (loss) per ordinary share | $ | (0.73) | $ | 0.17 | $ | (0.37) | $ | 0.49 | ||||||||
Weighted average ordinary shares outstanding used in | 11,453,845 | 11,329,516 | 11,454,512 | 11,369,031 | ||||||||||||
Weighted average ordinary shares outstanding used in | 11,453,845 | 11,738,884 | 11,454,512 | 11,777,139 | ||||||||||||
COLLPLANT BIOTECHNOLOGIES LTD. | ||||||||||
Six months ended | ||||||||||
2024 | 2023 | |||||||||
Cash flows from operating activities: | ||||||||||
Net income (loss) | $ | (8,405) | $ | 2,047 | ||||||
Adjustments to reconcile net income (loss) to net cash used in operating activities: | ||||||||||
Depreciation and amortization | 541 | 546 | ||||||||
Share-based compensation to employees and consultants | 780 | 852 | ||||||||
Net loss from financing expenses | 247 | 455 | ||||||||
Changes in operating asset and liability items: | ||||||||||
Increase in trade receivables | (250) | (10,151) | ||||||||
Decrease (increase) in inventories | 280 | (155) | ||||||||
Increase in other accounts receivable and prepaid expenses | (97) | (215) | ||||||||
Decrease in operating right of use assets | 295 | 254 | ||||||||
Increase (decrease) in trade payables | 158 | (370) | ||||||||
Decrease in lease liabilities | (397) | (435) | ||||||||
Decrease in accrued liabilities and other payables | (333) | (22) | ||||||||
Net cash used in operating activities | (7,181) | (7,194) | ||||||||
Cash flows from investing activities: | ||||||||||
Purchase of property and equipment | (284) | (482) | ||||||||
Investment in restricted deposits | (57) | (59) | ||||||||
Net cash used in investing activities | (341) | (541) | ||||||||
Cash flows from financing activities: | ||||||||||
Exercise of options and warrants into shares | 9 | 892 | ||||||||
Net cash provided by financing activities | 9 | 892 | ||||||||
Exchange differences on cash and cash equivalents and restricted cash | (241) | (444) | ||||||||
Net decrease in cash and cash equivalents and restricted cash | (7,754) | (7,287) | ||||||||
Cash and cash equivalents and restricted cash and at the beginning of the period | 26,674 | 29,653 | ||||||||
Cash and cash equivalents and restricted cash at the end of the period | $ | 18,920 | $ | 22,366 | ||||||
COLLPLANT BIOTECHNOLOGIES LTD. | ||||||||
Six months ended | ||||||||
2024 | 2023 | |||||||
Appendix to the statement of cash flows | ||||||||
A. Supplementary information on investing and financing activities not involving cash flows: | ||||||||
Right of use assets recognized with corresponding lease liabilities | $ | 623 | $ | 870 | ||||
Capitalization of Share-based compensation to inventory | $ | 5 | $ | 33 | ||||
B. Reconciliation of Cash, cash equivalents and restricted cash at the end of the period | ||||||||
Cash and cash equivalents | $ | 18,920 | $ | 22,283 | ||||
Restricted cash | - | 83 | ||||||
Total cash and cash equivalents and restricted cash | $ | 18,920 | $ | 22,366 | ||||
COLLPLANT BIOTECHNOLOGIES LTD.
| |||||||||
Six months ended | Three months ended | ||||||||
2024 | 2023 | 2024 | 2023 | ||||||
GAAP operating expenses: | $ | 8,001 | $ | 7,519 | $ | 4,119 | $ | 3,892 | |
Change of operating lease accounts | (14) | 33 | (15) | 12 | |||||
Share-based compensation to employees, | (780) | (852) | (490) | (338) | |||||
Non-GAAP operating expenses: | 7,207 | 6,700 | 3,614 | 3,566 | |||||
GAAP operating income (loss) | (8,735) | 2,158 | (4,406) | 5,677 | |||||
Change of operating lease accounts | 14 | (33) | 15 | (12) | |||||
Share-based compensation to employees, directors and consultants | 780 | 852 | 490 | 338 | |||||
Non-GAAP operating income (loss) | (7,941) | 2,977 | (3,901) | 6,003 | |||||
GAAP Net income (loss) | (8,405) | 2,047 | (4,210) | 5,762 | |||||
Change of operating lease accounts | (102) | (181) | (53) | (76) | |||||
Share-based compensation to employees, directors and consultants | 780 | 852 | 490 | 338 | |||||
Non-GAAP Net income (loss) | $ | (7,727) | $ | 2,718 | $ | (3,773) | $ | 6,024 | |
GAAP basic income (loss) per ordinary share | $ | (0.73) | $ | 0.18 | $ | (0.37) | $ | 0.51 | |
NON- GAAP basic income (loss) per ordinary share | $ | (0.67) | $ | 0.24 | $ | (0.33) | $ | 0.53 | |
GAAP diluted income (loss) per ordinary share | $ | (0.73) | $ | 0.17 | $ | (0.37) | $ | 0.49 | |
NON- GAAP diluted income (loss) per ordinary share | $ | (0.67) | $ | 0.23 | $ | (0.33) | $ | 0.52 | |
About CollPlant
CollPlant is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs, and medical aesthetics. The Company's products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant-based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing, and are ushering in a new era in regenerative and aesthetic medicine.
In 2021, CollPlant entered into a development and global commercialization agreement for dermal and soft tissue fillers with Allergan, an AbbVie company, the global leader in the dermal filler market.
For more information about CollPlant, visit http://www.collplant.com
Use of Non-US GAAP ("non-GAAP")
Financial results for 2024 and 2023 are presented on both a GAAP and a non-GAAP basis. GAAP results were prepared in accordance with
The presentation of this non-GAAP financial information is not intended to be considered in isolation or as a substitute for the financial information prepared and presented in accordance with GAAP. Management uses both GAAP and non-GAAP measures when operating and evaluating the Company's business internally and therefore decided to make these non-GAAP adjustments available to investors. The non-GAAP financial measures used by the Company in this press release may be different from the measures used by other companies.
For more information on the non-GAAP financial measures, please see the "Reconciliation of GAAP to Non-GAAP Financial Measures" in this release. This accompanying table has more details on the GAAP financial measures that are most directly comparable to non-GAAP financial measures and the related reconciliations between these financial measures.
The Company's consolidated financial statements for the first quarter ended June 30, 2024, are presented in accordance with generally accepted accounting principles in the
Forward-Looking Statements
This press release may include forward-looking statements. Forward-looking statements may include, but are not limited to, statements relating to CollPlant's objectives plans and strategies, as well as statements, other than historical facts, that address activities, events or developments that CollPlant intends, expects, projects, believes or anticipates will or may occur in the future. These statements are often characterized by terminology such as "believes," "hopes," "may," "anticipates," "should," "intends," "plans," "will," "expects," "estimates," "projects," "positioned," "strategy" and similar expressions and are based on assumptions and assessments made in light of management's experience and perception of historical trends, current conditions, expected future developments and other factors believed to be appropriate.
Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements. Many factors could cause CollPlant's actual activities or results to differ materially from the activities and results anticipated in forward-looking statements, including, but not limited to, the following: the Company's history of significant losses, its need to raise additional capital and its inability to obtain additional capital on acceptable terms, or at all; the Company's expectations regarding the costs and timing of commencing and/or concluding pre-clinical and clinical trials with respect to breast implants, tissues and organs which are based on its rhCollagen based BioInk and other products for medical aesthetics, and specifically the Company's ability to initiate its next large-animal study for its breast implants in a timely manner, or at all; the Company's or it strategic partners' ability to obtain favorable pre-clinical and clinical trial results; regulatory action with respect to rhCollagen based bioink and medical aesthetics products or product candidates including, but not limited to acceptance of an application for marketing authorization review and approval of such application, and, if approved, the scope of the approved indication and labeling; commercial success and market acceptance of the Company's rhCollagen based products, in 3D bioprinting and medical aesthetics; the Company's ability to establish sales and marketing capabilities or enter into agreements with third parties and its reliance on third party distributors and resellers; the Company's ability to establish and maintain strategic partnerships and other corporate collaborations, including its partnership with AbbVie and its ability to continue to receive milestone and royalties payments under the AbbVie agreement; the Company's reliance on third parties to conduct some or all aspects of its product development and manufacturing; the scope of protection the Company is able to establish and maintain for intellectual property rights and the Company's ability to operate its business without infringing the intellectual property rights of others; current or future unfavorable economic and market conditions and adverse developments with respect to financial institutions and associated liquidity risk; the impact of competition and new technologies; general market, political, and economic conditions in the countries in which the Company operates, including, with respect to the ongoing war in
Contacts:
CollPlant:
Eran Rotem
Deputy CEO & CFO
Tel: + 972-73-2325600
Email: Eran@collplant.com
Investors:
LifeSci Advisors
Dan Ferry
daniel@lifesciadvisors.com
Photo: https://mma.prnewswire.com/media/2485400/200_CC_vs_silicon_BI.jpg
Logo: https://mma.prnewswire.com/media/2217353/CollPlant_Logo.jpg
View original content to download multimedia:https://www.prnewswire.com/news-releases/collplant-biotechnologies-reports-2024-second-quarter-financial-results-and-provides-corporate-update-302226292.html
SOURCE CollPlant
FAQ
What were CollPlant's (CLGN) Q2 2024 financial results?
What progress did CollPlant (CLGN) make on its breast implant program in Q2 2024?
How long is CollPlant's (CLGN) current cash expected to last?
What was CollPlant's (CLGN) revenue in Q2 2024 compared to Q2 2023?
